Cytori Therapeutics Inc (NASDAQ:CYTX) Short Interest Update

Cytori Therapeutics Inc (NASDAQ:CYTX) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 226,800 shares, a growth of 49.0% from the June 15th total of 152,200 shares. Based on an average daily trading volume, of 583,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.8% of the shares of the company are sold short.

A number of research analysts recently issued reports on the company. Maxim Group restated a “hold” rating on shares of Cytori Therapeutics in a research note on Monday, April 1st. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.

NASDAQ:CYTX traded down $0.01 during mid-day trading on Friday, reaching $0.21. 444,400 shares of the stock were exchanged, compared to its average volume of 623,445. The company has a 50 day moving average of $0.24. The company has a quick ratio of 0.30, a current ratio of 0.46 and a debt-to-equity ratio of 0.39. Cytori Therapeutics has a 1 year low of $0.20 and a 1 year high of $0.75.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. Cytori Therapeutics had a negative return on equity of 272.70% and a negative net margin of 242.60%. The firm had revenue of $0.70 million for the quarter.

An institutional investor recently raised its position in Cytori Therapeutics stock. Virtu Financial LLC boosted its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 236.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 141,209 shares of the biotechnology company’s stock after acquiring an additional 99,279 shares during the quarter. Virtu Financial LLC owned about 0.86% of Cytori Therapeutics worth $36,000 as of its most recent filing with the Securities and Exchange Commission. 2.62% of the stock is owned by institutional investors and hedge funds.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.

Recommended Story: Leveraged Buyout (LBO)

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.